Pathophysiology of glomerular diseases
Our work is devoted to the study of human glomerular diseases, the leading causes of renal failure in the world, with two main axes around idiopathic nephrotic syndrome (axis 1) and nephro-oncology (axis 2).
In the first axis, the team studies the immunopathological mechanisms of glomerulopathies. Its work has made it possible to identify certain candidate genes for which animal models have been developed or are in progress. Current work aims to functionally characterize some of these models.
The team is also exploring the immuno-pathogenic link between environmental stress (infection, pollution) and flare-ups and relapses of idiopathic nephrotic syndrome.
The team’s second line of research aims to understand the pathogenic mechanisms underlying glomerulopathies induced by oncology therapies (chemotherapy or targeted biological treatments), at the cellular and molecular level. Indeed, this work involves the study of cell signalling pathways, as well as the study of communication between the different cell types of the glomerulus (podocytes, parietal epithelial cells, endothelial cells).
The team is developing innovative therapeutic approaches based on the treatment of experimental podocytopathies by nano-interference .
The team benefits from the coordination of the National Reference Centre for Idiopathic Nephrotic Syndrome and access to its cohorts and biobanks.
-New therapeutic approaches by nano-interference
9 Teacher-researchers and university hospitals
4 Hospital staff
3 PhD students
2 Administrative and technical staff
glomerulopathies, nephro-oncology, signalling, nano-interference
Oniszczuk J, Sendeyo K, Chhuon C, Savas B, Cogné E, Vachin P, Henique C, Chiara Guerrera I, Astarita G, Frontera V, Pawlak A, Audard V, Sahali D and Ollero M. CMIP is a negative regulator of T cell signaling.Cellular & Molecular Immunology, 2019; 10.1038/s41423-019-0266-5
Lazareth H, Henique C, Lenoir O, Puelles VG, Flamant M, Bollée G, Fligny C, Camus M, Guyonnet L, Millien C, Gaillard F, Chipont A, Robin B, Fabrega S, Dhaun N, Camerer E, Kretz O, Grahammer F, Braun F, Huber TB, Nochy D, Mandet C, Bruneval P, Mesnard L, Thervet E, Karras A, Le Naour F, Rubinstein E, Boucheix C, Alexandrou A, Moeller MJ, Bouzigues C, Tharaux PL. The tetraspanin CD9 controls migration and proliferation of parietal epithelial cells and glomerular disease progressionNat commun 10:3303, 2019
P Rémy, V Audard, P.A. Natella, G Pelle, B Dussol, H. Leray-Moragues, C.Vigneau, K. Bouachi, J. Dantal, L. Vrigneaud, A. Karras, F. Pourcine, P. Gatault, P. Grimbert, N. Ait Sahlia, E. Daugas, C. Combe, S. Bastuji-Garin and D. Sahali. Low dose steroid plus enteric-coated mycophenolate sodium versus high dose of steroid therapy for the treatment of Minimal Change Nephrotic Syndrome in adults (MSN Study): a French multicenter randomized controlled clinical trial (on behalf of the MSN trial investigators.).Kidney Int. 9: 1217-1226, 2018
Vachin P, Boumediene A, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, Pawlak A, Audard V, Ollero M, Guigonis V, Sahali D. NEPHRUTIX: A randomized, double-blind, placebo vs Rituximab-controlled trial assessing T-cell subset changes in Minimal Change Nephrotic Syndrome.J Autoimmun. 2017 Oct 19. pii: S0896-8411(17)30583-8. doi: 10.1016/j.jaut.2017.10.006.
C Hénique, G Bollée, X Loyer, F Grahammer, N Dhaun, M Camus, J Vernerey, F Gaillard, L Guyonnet, H Lazareth, C Meyer, I Bensaada, L Legrès, T Satoh, S Akira, P Bruneval, S Dimmeler, A Tedgui, A Karras, E Thervet, D Nochy, T Huber, L Mesnard, O Lenoir, and PL Tharaux*. Genetic and Pharmacological Inhibition of MicroRNA-92a Maintains Podocyte Cell Cycle Quiescence and Limits Crescentic GlomerulonephritisNat commun 8:1829, 2017
Moktefi, A., Zhang, S.Y., Vachin, P., Ory, V., Henique, C., Audard, V., Rucker-Martin, C., Gouadon, E., Eccles, M., Schedl, A., Heidet L, Ollero M, Sahali D, Pawlak A. 2016. Repression of CMIP transcription by WT1 is relevant to podocyte health.Kidney Int. 90:1298-1311, 2016
Mangier M, Izzedine H, Ory V, Zhang SY, Sendeyo K, Bouachi K, Audard V, Péchoux C, Soria JC, Massard C, Bahleda R, Bourry E, Khayat D, Baumelou A, Lang P, Ollero M, Pawlak A, Sahali D. Expression patterns of RelA and CMIP are associated with different glomerular diseases following anti-VEGF therapy.Kidney Int 85:457-70, 2014
Sahali D, Sendeyo K, Mangier M, Audard V, Zhang SY, Lang P, Ollero M, Pawlak A. Immunopathogenesis of idiopathic nephrotic syndrome with relapse.Semin Immunopathol 36:421-9, 2014.
- Responsable : Djillali Sahali
- Chercheur : André Pawlak
- Enseignant-Chercheur : Vincent Audard, Cécile Charrière-Bertrand, Carole Hénique-Gréciet, Sabine Le Gouvello, Anissa Moktefi, Mario Ollero, Djillali Sahali, Thomas Stehle
- Praticien hospitalier : Boutheina Ben Taarit, Djamal Dahmane, Khalil El Karoui, Hassan Izzedine
- Doctorant : Chloé Ben-Ali, Cérina Chhuon, Hamza Sakhi, Berkan Savas
- Ingénieur : Shao Yu Ambroise, Marion Morvan
- Gestionnaire : Véronique Baudot
- Stagiaire : Joanne Flejeo, Antoine Morel
IMRB – Inserm U955
Pathophysiology of glomerular diseases (Team Sahali)
Building R – Ground floor
Hôpital Henri Mondor
51, avenue du Maréchal De Lattre de Tassigny
Administrative assistant – Contact
Tél. : +33-1 49 81 37 71
Hepatocellular carcinoma is responsible for one third of cancer deaths worldwide, and most often develops in a context of chronic inflammation. While the immune microenvironment of tumours plays a decisive role in their evolution and is the subject of numerous studies, the role of immunity during the early stages of carcinogenesis remains little studied. In […]Read more
The family Bunyaviridae is a large but unfamiliar group of viruses with more than 300 members with a spherical and helical envelope. Viruses of this family can infect a wide range of hosts, from mosquitoes to marsupials and from thrips to tomatoes. Several of the Bunyaviridae cause serious disease in humans; they represent a growing […]Read more
VRI (Vaccine Research Institute)/ INSERM/UPEC (U955, IMRB) in collaboration with several Inserm and IRD teams has just published a study in Nature Communications on 24 July showing that Ebola survivors suffer serious immune system sequelae two years after their disease. Continuing to wreak havoc in the Democratic Republic of Congo four years after the […]Read more